Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
varnimcabtagene autoleucel
- Development stage
- Unknown
- Lead developer
- Immuneel Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Varnimcabtagene autoleucel (IMN-003A), frequently referred to by its clinical trial name **BROAD-CAR**, is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy. Developed by Immuneel Therapeutics in collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia (CHOP), it is designed to treat relapsed or refractory B-cell malignancies, including B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). The therapy utilizes a CAR construct featuring an anti-CD19 scFv (FMC63) linked to a 4-1BB (CD137) costimulatory domain and a CD3-zeta signaling domain. This specific construct is identical to the one used in tisagenlecleucel, which Immuneel licensed for development and manufacturing in India. The treatment involves genetically modifying a patient's own T cells to express the CAR, which then enables them to recognize and eliminate CD19-positive malignant B cells upon re-infusion. It is notable for being the first CAR-T cell therapy to undergo extensive clinical development and local manufacturing within India.
- Other names
- varnimcabtagene autoleucel
02
Targets
Beyond the preview
Go deeper on varnimcabtagene autoleucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on varnimcabtagene autoleucel.